Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Gains from Sales and Divestitures (2018 - 2024)

STRATA Skin Sciences' Gains from Sales and Divestitures history spans 7 years, with the latest figure at $2265.0 for Q4 2024.

  • For Q4 2024, Gains from Sales and Divestitures fell 87.38% year-over-year to $2265.0; the TTM value through Dec 2024 reached $2265.0, down 87.38%, while the annual FY2024 figure was $2265.0, 87.38% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2024 was $2265.0 at STRATA Skin Sciences, roughly flat from $2265.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $158407.0 in Q4 2022 and bottomed at $1414.0 in Q2 2024.
  • The 5-year median for Gains from Sales and Divestitures is $55547.0 (2020), against an average of $64465.6.
  • The largest annual shift saw Gains from Sales and Divestitures surged 298.66% in 2023 before it plummeted 98.23% in 2024.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $68091.0 in 2020, then skyrocketed by 114.95% to $146364.0 in 2021, then increased by 8.23% to $158407.0 in 2022, then crashed by 88.67% to $17944.0 in 2023, then crashed by 87.38% to $2265.0 in 2024.
  • Per Business Quant, the three most recent readings for SSKN's Gains from Sales and Divestitures are $2265.0 (Q4 2024), $2265.0 (Q3 2024), and $1414.0 (Q2 2024).